Adverum BiotechnologiesADVM
About: Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Employees: 155
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
100% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]
5.13% less ownership
Funds ownership: 81.45% [Q3] → 76.32% (-5.13%) [Q4]
9% less funds holding
Funds holding: 76 [Q3] → 69 (-7) [Q4]
27% less call options, than puts
Call options by funds: $45K | Put options by funds: $62K
38% less capital invested
Capital invested by funds: $120M [Q3] → $74.1M (-$46M) [Q4]
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Chardan Capital Daniil Gataulin 22% 1-year accuracy 11 / 50 met price target | 912%upside $33 | Buy Maintained | 17 Apr 2025 |
RBC Capital Luca Issi 20% 1-year accuracy 11 / 54 met price target | 53%upside $5 | Sector Perform Maintained | 16 Apr 2025 |
HC Wainwright & Co. Matthew Caufield 25% 1-year accuracy 17 / 68 met price target | 820%upside $30 | Buy Reiterated | 16 Apr 2025 |
Financial journalist opinion
Based on 35 articles about ADVM published over the past 30 days









